Cancer med. Cancer med. Response-adapted treatment with rituximab, bendamustine, mitoxantrone, and dexamethasone followed by rituximab maintenance in patients with relapsed or refractory follicular lymphoma after first-line immunochemotherapy: Results of the RBMDGELTAMO08 phase II trial Peñalver FJ Marquez JA Duran S Giraldo P Martin A Montalban C Sancho JM Ramirez MJ Terol MJ Capote FJ Gutierrez A Sanchez B Lopez A Salar A Rodriguez-Caravaca G Canales M Caballero MD Lopez JLB Carbonell F Bordas SF Lopez PF Persona EP Guillermo AL Martin RH Mayans JR Palomera L Universidad de Zaragoza Ceballos EP Hernandez JAQ Grau RR de la Cruz F Salinas AS 2019 research-article